Evaluating Immune Checkpoint Inhibition Response Biomarkers
Targeting the anti-tumor immune response has become a widely used strategy for the therapy of patients with advanced solid tumors, but not all patients respond, and immune-related side effects plus the high cost of these therapies increase the need for effective biomarkers to ensure that the immune checkpoint inhibitors are used in patients with the best chance of success. Clinicians need to be aware of the assays that are most appropriate to use based on the tumor type and the pitfalls of each testing technology.
Category
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Clinical Scenario #1: Applying Biomarkers in Risk Stratification of Localized Prostate Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
- Prostate Cancer
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Clinical Scenario #2: Applying Biomarkers in Breast Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
- Breast Cancer
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Clinical Scenario #3: Applying Biomarkers in Central Nervous System Cancers
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
- Central Nervous System Cancers
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
- Lung Cancers
Format
- Recorded Webcast
Credits
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC contact hours
- 0.75 Participation
What Drives Reimbursement for Biomarker Testing?
As the policy and coverage landscape evolves, healthcare professionals can benefit from understanding the implications of coverage policies for appropriate biomarker testing for their patients.
Category
Format
- Recorded Webcast
Credits
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
Archived Monthly Oncology Tumor Boards: Treatment of Patients with Kidney Cancer
Adjuvant treatment options for patients with advanced renal cell carcinoma (RCC) following surgery are continually evolving, and new treatment options for different stages of RCC are being approved. It can be challenging for clinicians to remain up-to-date on these updates.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease
Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.
Category
- Gastric/Esophageal Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Early Stage Breast Cancer
Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team.
Category
- Breast Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Archived Monthly Oncology Tumor Boards: Advances in Systemic Treatment of Metastatic Cutaneous Melanoma
The rapidly evolving treatment landscape for metastatic cutaneous melanoma is reflected in the new update of the NCCN Guidelines for Cutaneous Melanoma. Being familiar with the most current recommendations by the NCCN Panel will help clinicians in their multidisciplinary collaborations and to better support their patients.
Category
- Melanoma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation